Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulation of the FOLFIRI-based Standard First-line Therapy With Cetuximab, Controlled by Monitoring the RAS (Rat Sarcoma) Mutation Load by Liquid Biopsy in RAS-mutated mCRC (Metastatic Colorectal Cancer): A Randomized Phase II Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab (MoLiMoR)

NCT04554836 is registered in ClinicalTrials.gov with TheraOp as lead sponsor.

NCT NCT04554836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04554836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulation of the FOLFIRI-based Standard First-line Therapy With Cetuximab, Controlled by Monitoring the RAS (Rat Sarcoma) Mutation Load by Liquid Biopsy in RAS-mutated mCRC (Metastatic Colorectal Cancer): A Randomized Phase II Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab (MoLiMoR)
Lead sponsor
TheraOp
Phase
Phase 2
Overall status
Completed
Start date
December 29, 2020
Completion date
June 11, 2024
Enrollment
6 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the colon, adenocarcinoma of the rectum